Joining the data analytics bandwagon, the pharmaceutical giant Pfizer has launched their first clinical trial predictive modelling system which is aimed at reducing study risk during protocol design and to better study execution phases. In a recent interview Jonathan Rowe, the Executive Director and Head of Clinical Development Quality Performance and Risk Management of Pfizer shed some light on these predictive modelling systems.
When asked in the interview about the purpose of their predictive model and what it is meant to achieve, Rowe responded as follows…
It is true that there are quite a few models in the realm of GCP quality performance which we have developed and continue to refine. A relatively straightforward one is the correlation model where we correlate our clinical trial process performance to select the results of the GCP as is defined in the ICH E6. Continue reading “The 1st Clinical Trial Predictive Model By Pfizer is Here”